Van ECK Associates Corp Reduces Stake in Core Laboratories Inc. $CLB

Van ECK Associates Corp lowered its position in Core Laboratories Inc. (NYSE:CLB) by 16.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 393,682 shares of the oil and gas company’s stock after selling 78,784 shares during the period. Van ECK Associates Corp owned about 0.86% of Core Laboratories worth $4,586,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new position in Core Laboratories in the second quarter valued at about $86,910,000. Heartland Advisors Inc. bought a new stake in shares of Core Laboratories during the 2nd quarter valued at about $12,329,000. Goldman Sachs Group Inc. grew its stake in shares of Core Laboratories by 185.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock valued at $13,549,000 after purchasing an additional 548,657 shares during the period. Disciplined Growth Investors Inc. MN increased its position in shares of Core Laboratories by 9.7% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock valued at $73,787,000 after purchasing an additional 528,976 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Core Laboratories during the 2nd quarter valued at about $4,675,000. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Wall Street Analysts Forecast Growth

CLB has been the topic of a number of research reports. Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Finally, Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Thursday, August 13th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Buying and Selling

In other news, CEO Lawrence Bruno purchased 5,000 shares of the stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $10.78 per share, with a total value of $53,900.00. Following the completion of the acquisition, the chief executive officer directly owned 262,438 shares of the company’s stock, valued at $2,829,081.64. This trade represents a 1.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.26% of the company’s stock.

Core Laboratories Stock Performance

NYSE:CLB opened at $12.48 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The stock has a 50-day simple moving average of $11.61 and a two-hundred day simple moving average of $14.05. The firm has a market capitalization of $572.49 million, a PE ratio of 22.28, a P/E/G ratio of 2.45 and a beta of 1.08. Core Laboratories Inc. has a 52-week low of $9.79 and a 52-week high of $20.36.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The firm had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. During the same quarter last year, the company earned $0.19 earnings per share. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Analysts forecast that Core Laboratories Inc. will post 0.56 EPS for the current year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Monday, August 10th were paid a dividend of $0.01 per share. The ex-dividend date was Monday, August 10th. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is presently 7.14%.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.